Alnylam Pharmaceuticals Inc.

3 days ago · zacks.com

Alnylam's shares fall 25% despite Q3 beat as slower Amvuttra patient starts and demand concerns weigh on investor sentiment.

3 days ago · seekingalpha.com

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2026 Earnings Call Transcript

4 days ago · marketbeat.com

Alnylam Pharmaceuticals NASDAQ: ALNY reported third-quarter 2026 global net product revenue of approximately $1.3 billion, up 52% from a year earlier and 10% sequentially, as growth in its transthyretin, or TTR, franchise continued to drive results.

4 days ago · zacks.com

Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $16.26 per share, beating the Zacks Consensus Estimate of $2.19 per share. This compares to earnings of $2.9 per share a year ago.

4 days ago · zacks.com

While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

5 days ago · zacks.com

Get a deeper insight into the potential performance of Alnylam (ALNY) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

6 days ago · seekingalpha.com

Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease Transcript

7 days ago · marketbeat.com

Alnylam Pharmaceuticals NASDAQ: ALNY outlined early clinical data for brezosiran, an investigational RNA interference therapy for Huntington's disease, reporting dose-dependent reductions in cerebrospinal fluid mutant huntingtin after a single intrathecal dose and plans to begin a placebo-controlled pivotal study in 2027, pending regulatory alignment.

7 days ago · seekingalpha.com

Alnylam Pharmaceuticals, Inc.'s shares remain under pressure. Meanwhile, on October 23, Alnylam reported promising clinical data for brezosiran, its investigational treatment for Huntington's disease. Moreover, second-quarter Amvuttra sales surged 105.7% year-on-year to approximately $1.1 billion.

10 days ago · businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported positive initial Phase 1b clinical trial results for ALN-HTT02, an investigational RNAi therapeutic in development for the treatment of Huntington's disease, which will be developed under the International Nonproprietary Name (INN) brezosiran (bre-ZOH-sir-an). The data were presented in oral and poster presentations at the European Huntington's Disease Network (.